• Respondents answered a number of screening questions to determine whether they suffer from eczema on the hand(s).
• Respondents were classified as 'sufferers' if they had received a formal diagnosis of sCHE, but were also allowed to 'self-report' by selecting qualifying responses for length of time experiencing symptoms, frequency and duration of flares, affected hand surface area, and severity.
• Participants meeting the inclusion criteria were included in the full online survey, conducted in April 2014 (except China: June 2014).
-Inclusion criteria for the full survey included being aged 18-75 years old, a history of eczema/dry-skin/atopic-dermatitis on the hand/palm, the condition covering ≥1/4 of the most affected hand, symptoms for ≥1 year, ≥2 flares or symptom relapses per year, a flare duration ≥1 month and a self-rating of severe, very severe or even worse based on validated 5-point photographic scale developed by Coenraads et al. 2005. 3 • Questions on treatment and burden of disease were then answered by respondents who met the qualifying criteria for sCHE.
• To determine national prevalence, proportions were adjusted in line with population data to be nationally representative for each country.
• In India, 10 states with Hindi and English as the predominant language were surveyed and projected to a geographically representative population for these regions only; the two upper age groups (+55 years of age) for India were pooled, due to an under-representation of this age group.
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• Patients with severe chronic hand eczema (sCHE) may not recognize the disease as such, but experience a range of symptoms to varying degrees over extended periods. 1 • sCHE symptoms are often not fully-controlled by topical steroids and can have considerable impact on quality of life. 1, 2 • There is currently no universally accepted definition or classification for sCHE and the condition can be under-reported. 1 • Therefore, diagnosis remains problematic and resulting prevalence and burden data are limited.
• In order to overcome the lack of data, patients with sCHE were screened from adult consumer panels to examine the prevalence of sCHE, and to establish the 'patient journey' from initial consultation through to diagnosis and ongoing management.
Prevalence
• The screening survey was completed by 34,765 respondents across eight countries, of whom 147 had potential sCHE and completed the full survey; mean age was 43 years and mean duration of symptoms was 10.6 years ( Table 1) .
• The estimated prevalence of potential sCHE ranged from 0.13% to 0.8% and globally was estimated to be 0.54% (excluding Brazil*; Figure 1 ). • Through analysis of consumer panel data collected via online questionnaires, data regarding prevalence and other aspects of sCHE, a potentially underdiagnosed and under-reported condition, have been generated across eight countries.
• The prevalence estimates of patients with potential sCHE are consistent with those reported previously (0.5-0.7%); 1 variations across countries may reflect differences in patient care and medical practice in the countries studied.
• Limitations of this study include:
-The population was self-selecting, and therefore may include patients who are more likely to seek treatment.
-For some endpoints the number of patients was low, as would be expected for a disease with low prevalence. Therefore, some differences may be directional only.
-Online consumer panels tend to have lower representation of individuals with lower income and educational levels (e.g., Brazil in the case of this study). Supplementary 'pen and pencil' surveying may be beneficial in increasing representation and increasing sample size, although these can be costly and timeconsuming.
• However, the results demonstrate that this methodology is useful and pragmatic for the study of diseases or conditions for which data are limited and could be utilized to study other rare, taboo, or underdiagnosed conditions.
Conclusions
• The primary objective of this study was to rapidly generate global prevalence estimates for sCHE.
• Secondary objectives included examining treatment-seeking behavior patterns, establishing for how many patients the condition is not adequately managed with topical steroids, and assessing burden of disease. 
Objectives

Treatment
• Of patients with a diagnosis, 80% were receiving treatment; this ranged from 39%
(India) to 100% (France, Germany, Japan, and China) of patients.
• Among patients receiving treatment, just over half (55%) were estimated to be refractory to topical treatments.
Burden of disease
• The mean duration of symptoms was 10.6 years and ranged from 2.7 (India) to 18.0 (UK) years.
• Over 40% of patients suffer from symptoms continuously and all patients suffer at least twice a year.
• sCHE had an impact on many aspects of patients' lives (Figure 4) ; the impact was greatest overall for performing housework and hobbies, but impact on patients' social life/activities was greatest amongst patients in China, India, and Japan. 
Treatment-seeking behavior
• Overall, 0.46% respondents had a diagnosis of sCHE (Figure 1) .
• sCHE was diagnosed by a health care provider (HCP) in 53% of cases; of these HCPs, just over one-third (37%) were hospital-based dermatologists (Figure 2) .
-In China, 95% of patients received a diagnosis from a HCP, and in the majority of those cases were dermatologists (81%).
-Similarly, in India, 96% of patients received a diagnosis from a HCP; 64% of these were dermatologists.
-In contrast, in the UK and Germany, approximately one-third of patients were diagnosed with sCHE by a HCP (32 and 36%, respectively). 
